Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

Abstract

Pancreatic cancer is an aggressive, frequently fatal malignancy that strikes 37,000 patients annually in the U.S.A. It is poorly responsive to standard chemotherapies such as gemcitabine. Approximately 5-10% of pancreatic cancer occurs in the setting of a BRCA2 mutation. Breast and ovarian carcinomas that harbor BRCA2 mutations are susceptible to the effects of an emerging class of targeted agents, namely, poly(ADP-ribose) polymerase (PARP) inhibitors. This report describes the case of a patient with a germline BRCA2 mutation and an associated pancreatic cancer treated with iniparib (BSI-201), a PARP inhibitor, who demonstrated a complete pathologic response to this agent. This case highlights the potential benefit for PARP inhibition in BRCA2-related pancreatic cancer.

• Authors: David R Fogelman, Robert A Wolff, Scott Kopetz, Milind Javle, Charles Bradley, Isabel Mok, Fernando Cabanillas, James L Abbruzzese
• Journal: Anticancer research (Anticancer Res) Vol. 31 Issue 4 Pg. 1417-20 (Apr 2011) ISSN: 1791-7530 [Electronic] Greece
• PMID: 21508395 (Publication Type: Case Reports, Journal Article)

Chemical References

• BRCA2 Protein
• BRCA2 protein, human
• Benzamides
• Poly(ADP-ribose) Polymerase Inhibitors
• iniparib
• PARP1 protein, human
• Poly (ADP-Ribose) Polymerase-1

Topics

• Adenocarcinoma (genetics, secondary, therapy)
• BRCA2 Protein (genetics)
• Benzamides (therapeutic use)
• Breast Neoplasms (genetics, pathology, therapy)
• Female
• Germ-Line Mutation (genetics)
• Humans
• Middle Aged
• Neoplasm Recurrence, Local (genetics, pathology, therapy)
• Pancreatic Neoplasms (genetics, secondary, therapy)
• Poly (ADP-Ribose) Polymerase-1
• Poly(ADP-ribose) Polymerase Inhibitors
• Treatment Outcome